In a study pitting three of the newer anticoagulants for stroke prevention in patients with the common heart rhythm abnormality atrial fibrillation, gastrointestinal (GI) bleeds appeared to occur less often in the newest of the three. The blood thinners – Pradaxa, Xarelto and Eliquis – were the first novel anticoagulants (NOACs) to receive Food and Drug Administration (FDA) approval, in 2010, 2011 and 2012, respectively. Pradaxa, manufactured by Boehringer Ingelheim, contains the drug ingredient dabigatran. Xarelto, made by Johnson & Johnson’s Janssen Pharmaceuticals and Bayer, contains rivaroxaban. Eliquis, produced jointly by Bristol-Myers Squibb and Pfizer, contains the active ingredient apixaban. ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.